Editorial: Antimicrobial treatment of chronic bronchitis.
D000667:Ampicillin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D002908:Chronic Disease; D002981:Clindamycin / Q000627:therapeutic use; D004341:Drug Evaluation; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D010118:Oxytetracycline / Q000627:therapeutic use; D010403:Penicillin Resistance; D013291:Streptococcus / Q000187:drug effects; D013418:Sulfamethazine / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002981:Clindamycin; D013418:Sulfamethazine; D002701:Chloramphenicol; D000667:Ampicillin; D014295:Trimethoprim; D013752:Tetracycline; D010118:Oxytetracycline